A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01066468

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:12.133951+00:00

Published At

2012-03-13T00:00:00+00:00

Record Updated At

2012-03-13

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Chronic Myeloid Leukemia (CML)", "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)", "Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2012-03-13"

protocolSection.identificationModule.nctId

"NCT01066468"

protocolSection.identificationModule.officialTitle

"A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec\u00ae (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec\u00ae Indicated Hematological Disorders (HES, CEL, MDS/ MPN)"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Chronic Myeloid Leukemia (CML) (protocolSection.conditionsModule.conditions)
• Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (protocolSection.conditionsModule.conditions)
• Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.